Inhaled Treprostinil for PAH: Open-label Extension (INTREPID - OL)

United Therapeutics

Status and phase: Withdrawn; Phase 3

Conditions: Pulmonary Arterial Hypertension

Treatments: Drug: inhaled treprostinil

Study type: Interventional

Funder types: Industry

Identifiers

NCT01557660

RIN-PH-303

Details and patient eligibility

About

Open-label extension of RIN-PH-302.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Participation and completion of all required visits for study RIN-PH-302.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

inhaled treprostinil

Experimental group

Treatment:

Drug: inhaled treprostinil